MAIA Biotechnology Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat MAIA Biotechnology de winst en omzet met respectievelijk 3.5% en 155.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal dalen met 2.8% per jaar.

Belangrijke informatie

3.5%

Groei van de winst

-2.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	155.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	14 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

NYSEAM:MAIA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	65	-22	N/A	N/A	1
12/31/2025	N/A	-41	N/A	N/A	1
12/31/2024	N/A	-30	N/A	N/A	2
9/30/2024	N/A	-26	-16	-16	N/A
6/30/2024	N/A	-28	-15	-15	N/A
3/31/2024	N/A	-24	-13	-13	N/A
12/31/2023	N/A	-20	-13	-13	N/A
9/30/2023	N/A	-18	-12	-12	N/A
6/30/2023	N/A	-18	-13	-13	N/A
3/31/2023	N/A	-16	-13	-13	N/A
12/31/2022	N/A	-16	-12	-12	N/A
9/30/2022	N/A	-15	-11	-11	N/A
6/30/2022	N/A	-15	-8	-8	N/A
3/31/2022	N/A	-15	-7	-7	N/A
12/31/2021	N/A	-13	-4	-4	N/A
9/30/2021	N/A	-13	-3	-3	N/A
12/31/2020	N/A	-7	-2	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat MAIA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat MAIA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat MAIA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat MAIA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat MAIA volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MAIA naar verwachting over 3 jaar hoog zal zijn

MAIA Biotechnology Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology, Inc. announced that it expects to receive $2.439232 million in funding

MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

New major risk - Financial position

Maia Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Maia Biotechnology Reveals New Clinical Data Showing Thio’s Strong Efficacy in Non-Small Cell Lung Cancer

New major risk - Share price stability

MAIA Biotechnology, Inc. announced a financing transaction

MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC

MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $1.445 million.

MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAM:MAIA) announces an Equity Buyback for $0.8 million worth of its shares.

New major risk - Revenue and earnings growth

MAIA Biotechnology, Inc. Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Reports Updates on Preliminary Survival Data for Thio-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Files Second Patent for New Telomere-Targeting Molecules Program

Lead Independent Director recently bought US$300k worth of stock

MAIA Biotechnology, Inc. Announces it Intends to Initiate its Second Phase 2 Go-To-Market Trial Evaluating THIO

MAIA Biotechnology, Inc. Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Expands Phase 2 THIO-101 Trial to Europe

High number of new and inexperienced directors

MAIA Biotechnology, Inc. has completed an IPO in the amount of $10 million.

High number of new and inexperienced directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven